RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Using electronic health records to derive control arms for early phase single-arm lung cancer trials
Proof-of-concept in randomized controlled trials
Carrigan, G., Whipple, S., Capra, W. B., Taylor, M. D., Brown, J. S., Lu, M., Arnieri, B., Copping, R., & Rothman, K. J. (2020). Using electronic health records to derive control arms for early phase single-arm lung cancer trials: Proof-of-concept in randomized controlled trials. Clinical Pharmacology and Therapeutics, 107(2), 369-377. https://doi.org/10.1002/cpt.1586
Oncology drug development increasingly relies on single-arm clinical trials. External controls (ECs) derived from electronic health record (EHR) databases may provide additional context. Patients from a US-based oncology EHR database were aligned with patients from randomized controlled trials (RCTs) and trial-specific eligibility criteria were applied to the EHR dataset. Overall survival (OS) in the EC-derived control arm was compared with OS in the RCT experimental arm. The primary outcome was OS, defined as time from randomization or treatment initiation (EHR) to death. Cox regression models were used to obtain effect estimates using EHR data. EC-derived hazard ratio estimates aligned closely with those from the corresponding RCT with one exception. Comparing log HRs among all RCT and EC results gave a Pearson correlation coefficient of 0.86. Properly selected control arms from contemporaneous EHR data could be used to put single-arm trials of OS in advanced non-small cell lung cancer into context.
